Search research articles
Contact Us
Filters
Showing results (1-10 of 44) with videos related to
Page
of 5
Sort By:
Acta Haematologica
|
September 17, 2005
Future directions in multiple myeloma treatment
J Anthony Child, Nigel Russell, Pieter Sonneveld, et al.
Blood
|
May 27, 2006
Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials
Mark Drayson, Gulnaz Begum, Supratik Basu, et al.
British Journal of Haematology
|
January 16, 2007
Cyclooxygenase-2 (COX-2) in multiple myeloma: prognostic factor or therapeutic target?
Roger G Owen, Im Fan, Sheila J M O'connor, et al.
Haematologica
|
August 11, 2019
Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels
Jennifer L J Heaney, Alex Richter, Stella Bowcock, et al.
Haematologica
|
October 18, 2006
CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy
Andy C Rawstron, Giles Laycock-Brown, Geoff Hale, et al.
International Journal of Palliative Nursing
|
May 6, 2004
Home care versus hospital care in patients with multiple myeloma treated with pamidronate
Alastair G Smith, Richard L Soutar, Steven Schey, et al.
The New England Journal of Medicine
|
May 9, 2003
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
J Anthony Child, Gareth J Morgan, Faith E Davies, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 9, 2005
Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party
Bradley M Augustson, Gulnaz Begum, Janet A Dunn, et al.
Blood
|
May 1, 2004
Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses
Donald W Milligan, Savio Fernandes, Ranjit Dasgupta, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 16, 2011
Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma
K Jack Ishak, J Jaime Caro, Mark T Drayson, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 44) with videos related to
Sort By:
Page
of 5
Acta Haematologica
|
September 17, 2005
Future directions in multiple myeloma treatment
J Anthony Child, Nigel Russell, Pieter Sonneveld, et al.
Blood
|
May 27, 2006
Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials
Mark Drayson, Gulnaz Begum, Supratik Basu, et al.
British Journal of Haematology
|
January 16, 2007
Cyclooxygenase-2 (COX-2) in multiple myeloma: prognostic factor or therapeutic target?
Roger G Owen, Im Fan, Sheila J M O'connor, et al.
Haematologica
|
August 11, 2019
Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels
Jennifer L J Heaney, Alex Richter, Stella Bowcock, et al.
Haematologica
|
October 18, 2006
CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy
Andy C Rawstron, Giles Laycock-Brown, Geoff Hale, et al.
International Journal of Palliative Nursing
|
May 6, 2004
Home care versus hospital care in patients with multiple myeloma treated with pamidronate
Alastair G Smith, Richard L Soutar, Steven Schey, et al.
The New England Journal of Medicine
|
May 9, 2003
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
J Anthony Child, Gareth J Morgan, Faith E Davies, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 9, 2005
Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party
Bradley M Augustson, Gulnaz Begum, Janet A Dunn, et al.
Blood
|
May 1, 2004
Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses
Donald W Milligan, Savio Fernandes, Ranjit Dasgupta, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 16, 2011
Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma
K Jack Ishak, J Jaime Caro, Mark T Drayson, et al.
Page
of 5